In conclusion, our results suggest the role for IL-38 and IL-36Rα signaling in the colonic inflammation by effector immune cells and indicate that the IL-36Ra and IL-38 pathway may represent an innovative and rational target for therapeutic treatment in patients with IBD. Here, IL36RN is linked to inflammatory bowel disease.